Lilly Forteo "Approvable": Indications, Manufacturing Issues To Be Resolved
FDA and Lilly are continuing to discuss the appropriate patient populations for the osteoporosis agent Forteo, Lilly CEO Sidney Taurel told analysts Oct. 3.
FDA and Lilly are continuing to discuss the appropriate patient populations for the osteoporosis agent Forteo, Lilly CEO Sidney Taurel told analysts Oct. 3.